CHICAGO — In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5% over 24 weeks compared with placebo, according to the ...

Treatment with mifepristone led to improved glycemic control and weight loss in patients with poorly controlled T2D and hypercortisolism, according to new data from the CATALYST trial.

Mifepristone is a medication that reduces the effects of cortisol and is FDA approved for the treatment of elevated blood glucose in patients with hypercortisolism and prediabetes or type 2 diabetes.

What You Need To Know A federal appeals court upheld some limits on abortion medication mifepristone, setting up an eventual showdown at the Supreme Court The ruling by three judges on the 5th U.S ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed.